drugset / Trial / NCT05587361
Beta-Adrenergic Modulation of Drug Cue Reactivity
Phase 4
Recruiting
80 enrolled
University of Oklahoma
Duke University · collabNational Institute on Drug Abuse (NIDA) · collabNational Institutes of Health (NIH) · collabOklahoma State University Center for Health Sciences · collab
RandomizedCrossoverDouble-blindBasic science
Summary
This study is designed to investigate the effects of a beta-adrenergic antagonist (Propranolol; 40 mg IR) and nicotine patch (14 mg) administered alone and in combination on neurobiological and behavioral responses to smoking cues in ongoing cigarette smokers. This is a basic experimental study in humans and participants will not take these medications for an extended period or make a cessation attempt as part of their involvement in this research project.
Timeline
- Start
- 2024-11-26
- Primary completion
- 2027-03-31
- Completion
- 2027-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nicotine | Unknown | 14 mg | — |
| Subject | Propranolol | Small molecule | 40 mg | — |